Canaccord Genuity Reiterates a 'Buy' on Synta Pharma. (SNTA) Following Meeting with Management
Tweet
Share
E-mailGet Alerts SNTA Hot Sheet
Price: $0.34 --0%
Rating Summary:
4 Buy, 4 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Rating Summary:
4 Buy, 4 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Synta Pharma. (NASDAQ: SNTA) price target of $8.00.
Canaccord analyst, George Farmer, said, "Ahead of two critical clinical catalysts, we see 2012 as a potentially transformative year for the company. Per management, interim data from a Phase II trial evaluating lead asset ganetespib (g-pib), an hsp90 inhibitor, in advanced non-small cell lung cancer is expected year-end. This trial is enriched for patients predetermined to possess ALK growth-driving tumor mutations who would theoretically be candidates for treatment with newly approved ALK inhibitor, Xalkori (crizotinib; Pfizer (NYSE: PFE), as well."
For an analyst ratings summary and ratings history on Synta Pharma. click here. For more ratings news on Synta Pharma. click here.
Shares of Synta Pharma. closed at $4.61 yesterday.
Canaccord analyst, George Farmer, said, "Ahead of two critical clinical catalysts, we see 2012 as a potentially transformative year for the company. Per management, interim data from a Phase II trial evaluating lead asset ganetespib (g-pib), an hsp90 inhibitor, in advanced non-small cell lung cancer is expected year-end. This trial is enriched for patients predetermined to possess ALK growth-driving tumor mutations who would theoretically be candidates for treatment with newly approved ALK inhibitor, Xalkori (crizotinib; Pfizer (NYSE: PFE), as well."
For an analyst ratings summary and ratings history on Synta Pharma. click here. For more ratings news on Synta Pharma. click here.
Shares of Synta Pharma. closed at $4.61 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Downgrades IDP Education (IEL:AU) (IDPUF) to Hold
- Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results
- Nutanix (NTNX) PT Raised to $80 at Oppenheimer Into EPS
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
